Skip over navigation
Directory
Directory Search
Jobs
Job Search
Post a Job
Patient
Patient Resources
Drug Development
History
Genealogy
Toons & Teasers
About
Advertising
Home
Quick Links
Directory
Job Search
Toons & Teasers
Advertising
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Industry News
Search Articles:
Amgen provides update on status of ParsabivTM (Etelcalcetide) NDA Submitted to the FDA
Amgen announced the FDA has issued a Complete Response Letter for the New Drug Application for ParsabivTM (etelcalcetide) for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis.
August 24, 2016
More...
Email This Page
to a Friend
Print This
Page